Finding Optimal Targets for Complement-Based Cancer Therapy

Time: 10:00 am
day: Day Two


  • Despite strong preclinical evidence on a role of complement in promoting cancer, complement-based cancer therapies have not yet advanced to the clinic
  • Recent pre- and clinical studies suggest that progression of several subsets of renal cell carcinoma can be driven by complement-mediated mechanisms, therefore, these subsets are potential targets for complement-based intervention
  • Levels of complement fragments in plasma associate with the response to immune checkpoint inhibitors